A new study suggests that a common menopause treatment may influence how effectively certain weight-loss medications work.

Researchers at the University of California, Irvine Joe C. Wen School of Population & Public Health have identified how the hormone asprosin influences long-term weight change among postmenopausal ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: Spoiler alert: You can stop TRT — but the way you do so matters. Stopping abruptly ...

Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Over the past few years, a new class of medications has transformed the treatment of obesity. Drugs like Ozempic, Wegovy and Mounjaro work primarily by reducing appetite, helping people eat less and ...

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...

These brain areas are also linked to impulsivity and emotional control in people with ADHD. By reducing food cravings and constant thoughts about eating, GLP⁠-1s may help some people feel more focused ...

The drugs have names that sound like small planets: semaglutide, liraglutide, lixisenatide. Collectively, they belong to a class of glucagon-like peptide 1 (GLP-1) analogs that has reshaped the ...

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 ...

GLP-1 medications for weight loss are all the rage, but they come with some side effects. Here are my top 10 supplements I take everyday while on Zepbound.

A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.